These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 6743465

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
    Lennard MS, Jackson PR, Freestone S, Ramsay LE, Tucker GT, Woods HF.
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
    Lennard MS, Tucker GT, Silas JH, Woods HF.
    Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
    [Abstract] [Full Text] [Related]

  • 5. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.
    Lennard MS, McGourty JC, Silas JH.
    Br J Clin Pharmacol; 1988 Feb; 25(2):276-8. PubMed ID: 3358891
    [Abstract] [Full Text] [Related]

  • 6. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
    Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF.
    Br J Clin Pharmacol; 1985 Mar; 19(3):329-33. PubMed ID: 2859048
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
    Gleiter CH, Aichele G, Nilsson E, Hengen N, Antonin KH, Bieck PR.
    Br J Clin Pharmacol; 1985 Jul; 20(1):81-4. PubMed ID: 4027140
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL.
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP, Idle JR, Smith RL.
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [Abstract] [Full Text] [Related]

  • 19. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M, Idle JR, Teunissen MW, Sloan TP, Breimer DD, Smith RL.
    Pharmacology; 1981 Apr; 22(6):349-58. PubMed ID: 7267701
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.